Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report)‘s stock had its “overweight” rating restated by research analysts at Piper Sandler in a report released on Monday, Benzinga reports. They presently have a $20.00 price target on the stock, up from their prior price target of $19.00. Piper Sandler’s target price indicates a potential upside of 17.10% from the company’s current price.
Several other brokerages have also commented on TEVA. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 target price for the company in a research report on Friday, March 8th. StockNews.com lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Friday, May 10th. Jefferies Financial Group upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and boosted their target price for the company from $10.00 to $14.00 in a research note on Tuesday, January 23rd. Barclays boosted their target price on shares of Teva Pharmaceutical Industries from $17.00 to $20.00 and gave the company an “overweight” rating in a research note on Thursday, May 9th. Finally, The Goldman Sachs Group boosted their target price on shares of Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the company a “neutral” rating in a research note on Monday, February 5th. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $14.22.
Check Out Our Latest Research Report on TEVA
Teva Pharmaceutical Industries Trading Up 1.2 %
NYSE:TEVA opened at $17.08 on Monday. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.61 and a current ratio of 0.89. Teva Pharmaceutical Industries has a one year low of $7.09 and a one year high of $17.10. The business’s 50-day simple moving average is $13.95 and its 200 day simple moving average is $11.98. The stock has a market cap of $19.15 billion, a price-to-earnings ratio of -41.66, a price-to-earnings-growth ratio of 1.95 and a beta of 1.04.
Insider Activity
In other news, CEO Richard D. Francis sold 74,530 shares of the business’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $13.15, for a total transaction of $980,069.50. Following the completion of the transaction, the chief executive officer now owns 87,125 shares of the company’s stock, valued at $1,145,693.75. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, CEO Richard D. Francis sold 74,530 shares of the company’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $13.15, for a total value of $980,069.50. Following the completion of the sale, the chief executive officer now owns 87,125 shares of the company’s stock, valued at $1,145,693.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Eric Drape sold 9,815 shares of the company’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $13.12, for a total transaction of $128,772.80. Following the completion of the sale, the vice president now directly owns 9,701 shares of the company’s stock, valued at approximately $127,277.12. The disclosure for this sale can be found here. Over the last quarter, insiders sold 358,972 shares of company stock valued at $4,739,820. 0.55% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Teva Pharmaceutical Industries
Several institutional investors have recently bought and sold shares of TEVA. EntryPoint Capital LLC acquired a new stake in Teva Pharmaceutical Industries in the first quarter worth about $30,000. Blue Trust Inc. lifted its holdings in Teva Pharmaceutical Industries by 92.3% in the 4th quarter. Blue Trust Inc. now owns 4,541 shares of the company’s stock valued at $46,000 after acquiring an additional 2,180 shares during the last quarter. Signaturefd LLC lifted its holdings in Teva Pharmaceutical Industries by 90.8% in the 3rd quarter. Signaturefd LLC now owns 5,032 shares of the company’s stock valued at $51,000 after acquiring an additional 2,394 shares during the last quarter. Psagot Value Holdings Ltd. Israel acquired a new stake in Teva Pharmaceutical Industries in the 4th quarter valued at about $57,000. Finally, Newbridge Financial Services Group Inc….
Read More: Teva Pharmaceutical Industries (NYSE:TEVA) Stock Rating Reaffirmed by Piper